JP2022523530A - 化膿性汗腺炎の治療のための抗IL-α抗体 - Google Patents

化膿性汗腺炎の治療のための抗IL-α抗体 Download PDF

Info

Publication number
JP2022523530A
JP2022523530A JP2021550218A JP2021550218A JP2022523530A JP 2022523530 A JP2022523530 A JP 2022523530A JP 2021550218 A JP2021550218 A JP 2021550218A JP 2021550218 A JP2021550218 A JP 2021550218A JP 2022523530 A JP2022523530 A JP 2022523530A
Authority
JP
Japan
Prior art keywords
patients
subject
treatment
mabp1
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2021550218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523530A5 (cg-RX-API-DMAC7.html
Inventor
ギアマレロス-バーバリス・エバンゲロス・ジェイ
キム・スタンリー・エイ
Original Assignee
ヤンセン バイオテツク,インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク,インコーポレーテツド filed Critical ヤンセン バイオテツク,インコーポレーテツド
Publication of JP2022523530A publication Critical patent/JP2022523530A/ja
Publication of JP2022523530A5 publication Critical patent/JP2022523530A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021550218A 2019-02-28 2020-02-27 化膿性汗腺炎の治療のための抗IL-α抗体 Abandoned JP2022523530A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811696P 2019-02-28 2019-02-28
US62/811,696 2019-02-28
PCT/US2020/020115 WO2020176738A1 (en) 2019-02-28 2020-02-27 Anti-il-alpha antibody for the treatment of hidradenitis suppurativa

Publications (2)

Publication Number Publication Date
JP2022523530A true JP2022523530A (ja) 2022-04-25
JP2022523530A5 JP2022523530A5 (cg-RX-API-DMAC7.html) 2023-03-01

Family

ID=70110308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550218A Abandoned JP2022523530A (ja) 2019-02-28 2020-02-27 化膿性汗腺炎の治療のための抗IL-α抗体

Country Status (11)

Country Link
US (1) US20200277370A1 (cg-RX-API-DMAC7.html)
EP (1) EP3930752A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523530A (cg-RX-API-DMAC7.html)
KR (1) KR20210134927A (cg-RX-API-DMAC7.html)
CN (1) CN113905760A (cg-RX-API-DMAC7.html)
AU (1) AU2020228299A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016845A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131011A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010402A (cg-RX-API-DMAC7.html)
TW (1) TW202045537A (cg-RX-API-DMAC7.html)
WO (1) WO2020176738A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) * 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029003T2 (en) 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
MX394895B (es) 2014-06-03 2025-03-24 Xbiotech Inc Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
JP7145162B2 (ja) * 2017-02-16 2022-09-30 ヤンセン バイオテク,インコーポレイテッド 化膿性汗腺炎の処置

Also Published As

Publication number Publication date
WO2020176738A1 (en) 2020-09-03
AU2020228299A1 (en) 2021-09-09
BR112021016845A2 (pt) 2021-10-19
MX2021010402A (es) 2021-09-14
CA3131011A1 (en) 2020-09-03
KR20210134927A (ko) 2021-11-11
CN113905760A (zh) 2022-01-07
US20200277370A1 (en) 2020-09-03
TW202045537A (zh) 2020-12-16
EP3930752A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
US12116405B2 (en) Arthritis treatment
JP7145162B2 (ja) 化膿性汗腺炎の処置
US20200277370A1 (en) Treatment of hidradenitis suppurativa
JP2018515493A5 (cg-RX-API-DMAC7.html)
US20230235042A1 (en) Treatment of hidradenitis suppurativa
JP2022530063A (ja) 抗体製剤
RU2772202C2 (ru) Лечение гнойного гидраденита
WO2025083621A1 (en) Treatment of hidradenitis suppurativa using anti-baff-r antibodies
EA044851B1 (ru) Антитела против хемокинов pan-elr+ cxc для лечения гнойного гидраденита
AU2017200039A1 (en) Arthritis treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230220

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20231016